David Rind, ICER CMO
ICER finds GSK inhalers offer advantages over generic competitors
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations are justified because of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
